February 15, 2024
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
January 03, 2024
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorpha...
December 14, 2023
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
In recognition of International Day of Women & Girls in Science, Laura Tan reflects on her career journey and the importance of creating opportunities for women in STEM.
Blair Jackson shares his thoughts on Alkermes' past and future as a neuroscience company.
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.